High plasma concentrations of osteopontin in patients with interstitial pneumonia

J Kadota1, S Mizunoe, K Mito

  • 1Division of Pathogenesis and Disease Control, Department of Infectious Diseases, Faculty of Medicine, Oita University, 1-1 Hasama, Oita 879-5593, Japan. kadota@med.oita-u.ac.jp

Respiratory Medicine
|January 28, 2005
PubMed

Insights

Plasma osteopontin (OPN) levels are elevated in interstitial pneumonia (IP) patients, correlating with disease severity. This suggests OPN may be a key biomarker and factor in IP development.

Area of Science:

  • Pulmonary Medicine
  • Immunology
  • Biomarker Discovery

Background:

  • Osteopontin (OPN) is implicated as a fibrogenic cytokine in bleomycin-induced pulmonary fibrosis.
  • OPN mRNA is detected in lung tissues of idiopathic pulmonary fibrosis (IPF) patients.
  • The role of plasma OPN levels in human interstitial pneumonia (IP) requires further investigation.

Purpose of the Study:

  • To investigate plasma osteopontin (OPN) levels in patients with interstitial pneumonia (IP).
  • To assess the relationship between plasma OPN concentrations and disease severity in IP.
  • To analyze the correlation between plasma OPN levels and pulmonary function parameters.

Main Methods:

  • Plasma OPN concentrations were measured using an antigen-capture enzyme-linked immunosorbent assay (ELISA).
  • Measurements were performed in 17 IP patients, 9 sarcoidosis patients, and 20 healthy controls.
  • Receiver Operating Characteristic (ROC) curve analysis was used to determine diagnostic cut-off points.

Main Results:

  • Plasma OPN levels were significantly higher in IP patients compared to sarcoidosis patients and healthy controls.
  • ROC analysis identified cut-off points (300-380 ng/ml) with 100% sensitivity and specificity for distinguishing IP from controls.
  • Plasma OPN levels showed an inverse correlation with arterial oxygen tension (PaO2) in IP patients.

Conclusions:

  • Elevated plasma osteopontin (OPN) levels are associated with the presence of interstitial pneumonia (IP).
  • OPN may play a significant role in the pathogenesis and development of IP.
  • Plasma OPN shows potential as a diagnostic biomarker for IP, correlating with disease severity.

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...